xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06020326</url>
    </required_header>
    <id_info>
      <org_study_id>REHEAL</org_study_id>
      <nct_id>NCT06020326</nct_id>
    </id_info>
    <brief_title>A Retrospective Cohort Study of HFRS</brief_title>
    <official_title>A Retrospective Cohort Study of Hemorrhagic Fever With Renal Syndrome</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Tongji Hospital</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Tongji Hospital</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this retrospective cohort study is to learn about the clinial characteristics of&#xD;
        HFRS patients, explore the risk factors of the occurrence and death of HFRS, and build a risk&#xD;
        prediction model for HFRS.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        HFRS remains an important public health issue in China, which not only poses a threat to&#xD;
        people's physical health and safety, but also has a serious impact on social and economic&#xD;
        development. At present, there is no unified standard for clinical prediction of the&#xD;
        occurrence and death of HFRS. In order to better prevent and treat HFRS, this multicenter&#xD;
        retrospective clinical study is designed to include HFRS inpatients, and collect their&#xD;
        demographics, epidemiological history, hospitalization information, clinical manifestation,&#xD;
        laboratory results, imaging results, treatment plan and outcome.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">May 5, 2022</start_date>
    <completion_date type="Anticipated">December 31, 2023</completion_date>
    <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Retrospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>short-term mortality</measure>
      <time_frame>90 days post diagnosed HFRS</time_frame>
      <description>28-day and 90-day mortality after diagnosed as HFRS</description>
    </primary_outcome>
    <enrollment type="Anticipated">500</enrollment>
    <condition>HFRS</condition>
    <eligibility>
      <study_pop>
        <textblock>
          Inpatients with HFRS diagnosed&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          The patients must meet all of the following criteria:&#xD;
  &#xD;
            -  Inpatient with clinical diagnosis of Haemorrhagic Fever with Renal Syndrome&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          Exclude patients who meet any of the following criteria:&#xD;
  &#xD;
            -  Patients with previous chronic kidney disease&#xD;
  &#xD;
            -  Pregnant or perinatal patients&#xD;
  &#xD;
            -  Patients unsuitable for inclusion by investigators' evaluation&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Qin Ning, Professor</last_name>
      <role>Principal Investigator</role>
      <affiliation>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp; Technology</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Qin Ning, Professor</last_name>
      <phone>+8613971521450</phone>
      <email>qning@vip.sina.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>No.1 Peoples Hospital of Guangshui</name>
        <address>
          <city>Guangshui</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Qian Liu</last_name>
        <phone>13872857607</phone>
        <email>liuqian060685@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Huanggang Central Hospital</name>
        <address>
          <city>Huanggang</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Xiang Guo Zhu</last_name>
        <phone>18602786696</phone>
        <email>526896352@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>People's Hospital of Luotian County</name>
        <address>
          <city>Huanggang</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Wei Wang</last_name>
        <phone>13409767486</phone>
        <email>196436547@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>People's Hospital of Macheng City, Affiliated Hospital of Hubei University of Science and Technology</name>
        <address>
          <city>Macheng</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Yi Zhou</last_name>
        <phone>19971181214</phone>
        <email>2513478349@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Qianjiang Central Hospital</name>
        <address>
          <city>Qianjiang</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Jun Wang</last_name>
        <phone>13451145526</phone>
        <email>qjn6249223@163.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp; Technology</name>
        <address>
          <city>Wuhan</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Qin Ning</last_name>
        <phone>+8613971521450</phone>
        <email>qning@vip.sina.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Xianning Central Hospital</name>
        <address>
          <city>Xianning</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Jun Zhu</last_name>
        <phone>13117160652</phone>
        <email>1356266581@qq.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>The Third Peoples Hospital of Yichang</name>
        <address>
          <city>Yichang</city>
          <state>Hu Bei Province</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Quan Ming</last_name>
        <phone>13872658268</phone>
        <email>737695825@qq.com</email>
      </contact>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>August 17, 2023</study_first_submitted>
    <study_first_submitted_qc>August 27, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 31, 2023</study_first_posted>
    <last_update_submitted>August 27, 2023</last_update_submitted>
    <last_update_submitted_qc>August 27, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 31, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Tongji Hospital</investigator_affiliation>
      <investigator_full_name>Qin Ning</investigator_full_name>
      <investigator_title>Director, Department of Infection</investigator_title>
    </responsible_party>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06020326
  org study id: REHEAL
  nct id: NCT06020326
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this retrospective cohort study is to learn about the clinial characteristics of
        HFRS patients, explore the risk factors of the occurrence and death of HFRS, and build a risk
        prediction model for HFRS.
  HFRS remains an important public health issue in China, which not only poses a threat to
        people's physical health and safety, but also has a serious impact on social and economic
        development. At present, there is no unified standard for clinical prediction of the
        occurrence and death of HFRS. In order to better prevent and treat HFRS, this multicenter
        retrospective clinical study is designed to include HFRS inpatients, and collect their
        demographics, epidemiological history, hospitalization information, clinical manifestation,
        laboratory results, imaging results, treatment plan and outcome.
  observational model: Cohort
  time perspective: Retrospective
  measure: short-term mortality
  time frame: 90 days post diagnosed HFRS
  description: 28-day and 90-day mortality after diagnosed as HFRS
  study pop: 
  sampling method: Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Qin Ning, Professor
  role: Principal Investigator
  affiliation: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
  last name: Qin Ning, Professor
  phone: +8613971521450
  email: qning@vip.sina.com
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  country: China
  responsible party type: Principal Investigator
  investigator affiliation: Tongji Hospital
  investigator full name: Qin Ning
  investigator title: Director, Department of Infection